2021. Muñoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Montaño O, Quintana-Hau JD, Baiza-Duran L. Pharmacokinetics and safety of an intravitreal humanized anti-VEGF-A monoclonal antibody (PRO-169), a biosimilar candidate to Bevacizumab. J Exp Pharmacol. 13: 545 – 54. DOI: 10.2147/JEP.S308388.

2020. Belalcázar-Rey S, Sánchez-Huerta V, Ochoa-Tabares JC, Altamirano Vallejo S, Soto- Gómez A, Suárez-Velasco R, García-Féliz F, Baiza-Durán L, Olvera-Montaño O, Muñoz-Villegas P. Efficacy and safety of sodium hyaluronate/chondroitin sulfate preservative-free ophthalmic solution in the treatment of dry eye: a clinical trial. Curr Eye Res. 8:1-11. DOI: 10.1080/02713683.2020.1849733.

2020. Baiza-Durán L, Sánchez-Ríos A, González-Barón J, Olvera-Montaño O, Correa- Gallegos E, Navarro-Sánchez A, Muñoz-Villegas P. Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits. Int J Retina Vitreous. 28; 6:32. DOI: 10.1186/s40942-020-00235-y.

2020. Palacio-Pastrana C, Chávez-Mondragón E, Soto-Gómez A, Suárez-Velasco R, Montes-Salcedo M, Fernández de Ortega L, Nasser-Nasser L, Baiza-Durán L, Olvera- Montaño O, MuñozVillegas P. Difluprednate 0.05% versus prednisolone acetate post-phacoemulsification for inflammation and pain: an efficacy and safety Clinical trial. Clin Ophthalmol. 14:1581-1589. DOI: 10.2147/OPTH.S254705.

2019. Olvera-Montaño O, Baiza-Duran L, Quintana-Hau JD, Quiñonez-Alvarado MG, Zen W, Gong L, Muñoz-Villegas P. Comparing the efficacy of an anti-human VEGF-A neutralizing antibody versus Bevacizumab on a laser-induced choroidal neovascularization (CNV) rhesus monkey model. Drug Des Devel Ther, 13: 3813-3821. DOI: 10.2147/DDDT.S219350.

2019. Chávez-Mondragón E, Palacio C, Muñoz-Villegas P, et al. Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination Therapy, versus placebo in patients with pterygium I-III for clinical signs on ocular inflammation. Clin Ophthalmol; 13: 781-87. DOI: 10.2147/OPTH.S203648.

2018. Duart-Castells L, López-Arnau R, Buenrostro-Jáuregui M, Muñoz-Villegas P, Valverde O, Camarasa J, Pubill D, Escubedo E. Neuroadaptive changes and behavioral effects after a sensitization regime of MDPV. Neuropharmacology, 144: 271-81. DOI: 10.1016/j.neuropharm.2018.10.005.

2018. Gómez-Aguayo F, Paczka JA, Leñero-Córdova R, Jiménez-Román J, Dávila-Villerreal J, Hartleben C, Baiza-Durán L, Olvera-Montaño O, García-Velez F, Muñoz-Villegas P. A phase III randomized clinical trial of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination in patients with controlled primary open-angle
glaucoma. Ophthalmol Ther, 7(1): 145-56. DOI: 10.1007/s40123-018-0128-8.

2018. Sanchez-Castellanos VE, Paczka JA, Gomez-Aguayo F, Gil-Carrasco F, Hartleben C, baizaDurán L, Olvera-Montaño O, Sánchez-Ríos A, Muñoz-Villegas P. A phase III, randomized, clinical, crossover study to evaluate the non-inferiority of an ophthalmic solution of preservative-free latanoprost at 0.005% in patients with primary open-angle glaucoma. New Front Ophthalmol. 4: DOI: 10.15761/NFO.1000202.

2017. López-Arnau R, Buenrostro-Jáuregui M, Muñoz-Villegas P, Rodríguez-Morató J, CiudadRoberts A, Duart L, Camarasa J, De la Torre R, Pubill D, Escubedo E. The combination of MDPV and ethanol results in decreased cathinone and increased alcohol levels. Study of such pharmacological interaction. Prog Neuropsychopharmacol Biol Psychiatry, 76:19-28. DOI: 10.1016/j.pnpbp.2017.02.011.

2017. Muñoz-Villegas P, Rodríguez VM, Giordano M, Juárez J. Risk-taking, locomotor activity and dopamine levels in the Nucleus Accumbens and medial Prefrontal Cortex in rats treated prenatally with alcohol. Pharmacol Biochem Behav, 153: 88–96. DOI: 10.1016/j.pbb.2016.12.011.

2016. Buenrostro-Jáuregui M, Ciudad-Roberts A, Moreno J, Muñoz-Villegas P, López- Arnau R, Pubill D, Escubedo E, Camarasa J. Changes in CREB and deltaFosB are associated with the behavioural sensitization induced by methylenedioxypyrovalerone. J Psychopharmacol, 30(7): 707-12. DOI: 10.1177/026988116645300.